Nanoparticle-based delivery of carbamazepine: A promising approach for the treatment of refractory epilepsy

Zybina, Anna; Anshakova, A. V.; Malinovskaya, Julia; Melnikov, Pavel; Baklaushev, V. P.; Chekhonin, V. P.; Maksimenko, Olga; Титов, С. В.; Balabanyan, Vadim; Kreuter, Jörg; Gelperina, Svetlana; Abbasova, Kenul

doi:10.1016/j.ijpharm.2018.05.023

Cited by 39 publications

(30 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…L-Type amino acid transporter 1 (LAT1) is up-regulated due to the huge consumption for tryptophan in epileptogenic focus for the aberrant activation of kynurenine pathway to synthesize kynurenic acid and quinolinic acid 62 . Specific up-regulation of multidrug efflux transporter P-gp is another important BBB evolution in epilepsy 61 , 62 , 63 , 64 . Loss of TJ and increased microvascular density were also observed in temporal lobe epilepsy 18 .…”

Section: Normal Bbb and Diseased Bbbmentioning

confidence: 99%

“…Integrin receptors for angiogenesis are increased on reactive brain capillary endothelial cells in PD, ischemia and brain tumors 54 , 73 , 119 , which makes it feasible to use related ligands to mediate the crossing of the diseased BBB in these lesions. Epilepsy-specific overexpression of multidrug efflux transporters, such as P-gp, reduces intracranial concentrations of antiepileptic drugs 62 , 63 , 64 , and should be emphasized when designing drug delivery systems for epilepsy. The reduced GLUT1 and LDLR-related protein 1 (LRP1) on the BBB in AD may need to be reversed to strengthen the BBB crossing efficiency of glucose-modified nanocarriers or angiopep-2-modified nanocarriers.…”

Section: Diseased Bbb-based Brain-targeting Delivery Strategiesmentioning

confidence: 99%

See 1 more Smart Citation

Evolution of blood–brain barrier in brain diseases and related systemic nanoscale brain-targeting drug delivery strategies

Han

Jiang

2021

Acta Pharmaceutica Sinica B

203

105

View full text Add to dashboard Cite

Blood–brain barrier (BBB) strictly controls matter exchange between blood and brain, and severely limits brain penetration of systemically administered drugs, resulting in ineffective drug therapy of brain diseases. However, during the onset and progression of brain diseases, BBB alterations evolve inevitably. In this review, we focus on nanoscale brain-targeting drug delivery strategies designed based on BBB evolutions and related applications in various brain diseases including Alzheimer's disease, Parkinson's disease, epilepsy, stroke, traumatic brain injury and brain tumor. The advances on optimization of small molecules for BBB crossing and non-systemic administration routes ( e . g ., intranasal treatment) for BBB bypassing are not included in this review.

show abstract

Section: Normal Bbb and Diseased Bbbmentioning

confidence: 99%

Section: Diseased Bbb-based Brain-targeting Delivery Strategiesmentioning

confidence: 99%

Evolution of blood–brain barrier in brain diseases and related systemic nanoscale brain-targeting drug delivery strategies

Han

Jiang

2021

Acta Pharmaceutica Sinica B

203

105

View full text Add to dashboard Cite

show abstract

“…Inhibition of efflux transporters at the BBB can enhance the brain concentration of the substrate drugs which might lead to unwanted and serious CNS side effects from the compounds and also in other cases can provide a therapeutic advantage. However, the delivery of an anticonvulsant, encapsulated carbamazepine NPs was not affected by the inhibition of P-gp, because NPs circumvented the transporters of the BBB [212].…”

Section: Efflux Transporter Inhibitionmentioning

confidence: 99%

Overcoming the Blood–Brain Barrier. Challenges and Tricks for CNS Drug Delivery

2019

View full text Add to dashboard Cite

Treatment of certain central nervous system disorders, including different types of cerebral malignancies, is limited by traditional oral or systemic administrations of therapeutic drugs due to possible serious side effects and/or lack of the brain penetration and, therefore, the efficacy of the drugs is diminished. During the last decade, several new technologies were developed to overcome barrier properties of cerebral capillaries. This review gives a short overview of the structural elements and anatomical features of the blood–brain barrier. The various in vitro (static and dynamic), in vivo (microdialysis), and in situ (brain perfusion) blood–brain barrier models are also presented. The drug formulations and administration options to deliver molecules effectively to the central nervous system (CNS) are presented. Nanocarriers, nanoparticles (lipid, polymeric, magnetic, gold, and carbon based nanoparticles, dendrimers, etc.), viral and peptid vectors and shuttles, sonoporation and microbubbles are briefly shown. The modulation of receptors and efflux transporters in the cell membrane can also be an effective approach to enhance brain exposure to therapeutic compounds. Intranasal administration is a noninvasive delivery route to bypass the blood–brain barrier, while direct brain administration is an invasive mode to target the brain region with therapeutic drug concentrations locally. Nowadays, both technological and mechanistic tools are available to assist in overcoming the blood–brain barrier. With these techniques more effective and even safer drugs can be developed for the treatment of devastating brain disorders.

show abstract

“…A previous study also reports that treatment of epileptic rat model with pluronic P85-coated PBCA NPs alleviates the effects of P-gp in phenyltoin resistance and increases its bioavailability (Fang et al, 2016). The loading of carbamazepine (an anticonvulsant drug used to treat epilepsy) into the poloxamer 188-coated PLGA NPs also improves the drug effect in isoniazid-induced epilepsy rat model compared to the administration of free drug (Zybina et al, 2018). Further evidence suggests that the treatment with quercetin-conjugated IO-β-cyclodextrin NPs can markedly enhance the therapeutic effect of quercetin in epileptic mouse model (Hashemian et al, 2019).…”

Section: Epilepsymentioning

confidence: 94%

The Application of Nanotechnology for the Diagnosis and Treatment of Brain Diseases and Disorders

Ngowi

Wang

Qian

et al. 2021

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Brain is by far the most complex organ in the body. It is involved in the regulation of cognitive, behavioral, and emotional activities. The organ is also a target for many diseases and disorders ranging from injuries to cancers and neurodegenerative diseases. Brain diseases are the main causes of disability and one of the leading causes of deaths. Several drugs that have shown potential in improving brain structure and functioning in animal models face many challenges including the delivery, specificity, and toxicity. For many years, researchers have been facing challenge of developing drugs that can cross the physical (blood–brain barrier), electrical, and chemical barriers of the brain and target the desired region with few adverse events. In recent years, nanotechnology emerged as an important technique for modifying and manipulating different objects at the molecular level to obtain desired features. The technique has proven to be useful in diagnosis as well as treatments of brain diseases and disorders by facilitating the delivery of drugs and improving their efficacy. As the subject is still hot, and new research findings are emerging, it is clear that nanotechnology could upgrade health care systems by providing easy and highly efficient diagnostic and treatment methods. In this review, we will focus on the application of nanotechnology in the diagnosis and treatment of brain diseases and disorders by illuminating the potential of nanoparticles.

show abstract

Nanoparticle-based delivery of carbamazepine: A promising approach for the treatment of refractory epilepsy

Cited by 39 publications

References 54 publications

Evolution of blood–brain barrier in brain diseases and related systemic nanoscale brain-targeting drug delivery strategies

Evolution of blood–brain barrier in brain diseases and related systemic nanoscale brain-targeting drug delivery strategies

Overcoming the Blood–Brain Barrier. Challenges and Tricks for CNS Drug Delivery

The Application of Nanotechnology for the Diagnosis and Treatment of Brain Diseases and Disorders

Contact Info

Product

Resources

About